[go: up one dir, main page]

MX2016006955A - Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo. - Google Patents

Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo.

Info

Publication number
MX2016006955A
MX2016006955A MX2016006955A MX2016006955A MX2016006955A MX 2016006955 A MX2016006955 A MX 2016006955A MX 2016006955 A MX2016006955 A MX 2016006955A MX 2016006955 A MX2016006955 A MX 2016006955A MX 2016006955 A MX2016006955 A MX 2016006955A
Authority
MX
Mexico
Prior art keywords
methods
graft versus
treating
versus host
host disease
Prior art date
Application number
MX2016006955A
Other languages
English (en)
Other versions
MX389020B (es
Inventor
R Blazar Bruce
Flynn Ryan
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2016006955A publication Critical patent/MX2016006955A/es
Publication of MX389020B publication Critical patent/MX389020B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen aquí métodos para tratar y evitar enfermedad crónica de injerto versus anfitrión impulsada por aloanticuerpo (cGVHD). Los métodos incluyen administrar a un individuo en necesidad de los mismos ibrutinib para tratar y evitar enfermedad de injerto versus anfitrión impulsada por aloanticuerpo.
MX2016006955A 2013-12-02 2014-12-02 Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo. MX389020B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361910944P 2013-12-02 2013-12-02
US201461973178P 2014-03-31 2014-03-31
PCT/US2014/068177 WO2015084857A1 (en) 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease

Publications (2)

Publication Number Publication Date
MX2016006955A true MX2016006955A (es) 2016-09-07
MX389020B MX389020B (es) 2025-03-20

Family

ID=53270044

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006955A MX389020B (es) 2013-12-02 2014-12-02 Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo.
MX2022000209A MX2022000209A (es) 2013-12-02 2016-05-27 Uso de ibrutinib en el tratamiento del sindrome de bronquiolitis obliterante.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000209A MX2022000209A (es) 2013-12-02 2016-05-27 Uso de ibrutinib en el tratamiento del sindrome de bronquiolitis obliterante.

Country Status (14)

Country Link
US (6) US20150157634A1 (es)
EP (1) EP3076975A4 (es)
JP (5) JP2017501140A (es)
KR (2) KR20230104754A9 (es)
CN (2) CN105939717B (es)
AU (4) AU2014360758B2 (es)
BR (1) BR112016012158A2 (es)
CA (2) CA3210338A1 (es)
EA (1) EA201691020A1 (es)
IL (4) IL292522A (es)
MX (2) MX389020B (es)
PH (2) PH12020552048A1 (es)
TW (3) TW202402295A (es)
WO (1) WO2015084857A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014030424A8 (pt) 2012-06-04 2017-07-11 Pharmacyclics Inc Formas cristalinas de um inibidor de quinase de tirosina de bruton
KR102452866B1 (ko) * 2013-10-25 2022-10-07 파마싸이클릭스 엘엘씨 이식편 대 숙주 질환의 치료 및 예방 방법
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
WO2017165497A1 (en) * 2016-03-22 2017-09-28 Leof Edward B Using fatty acid synthase inhibitors to treat fibrosis
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
WO2018075888A1 (en) * 2016-10-21 2018-04-26 Regents Of The University Of Minnesota Materials and methods for treating or preventing graft-versus-host-disease
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US12496303B2 (en) 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
WO2022119931A1 (en) * 2020-12-01 2022-06-09 City Of Hope Prevention and treatment of graft-versus-host disease (gvhd)
WO2022161484A1 (en) * 2021-01-30 2022-08-04 Beigene, Ltd. Methods of treating chronic active antibody-mediated rejection using btk inhibitors
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
EP1981888A4 (en) * 2006-01-13 2010-10-13 Pharmacyclics Inc TYROSINE KINASE INHIBITORS AND USES THEREOF
ES2585902T3 (es) 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
CN102159214A (zh) * 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
JP5656976B2 (ja) * 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
CN102666581A (zh) * 2009-08-31 2012-09-12 艾普利穆恩公司 用于抑制移植物排斥的方法和组合物
NZ702485A (en) * 2010-06-03 2016-04-29 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
KR20140058543A (ko) * 2011-07-08 2014-05-14 노파르티스 아게 신규 피롤로 피리미딘 유도체
HK1206624A1 (en) * 2012-04-11 2016-01-15 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
US10722577B2 (en) * 2012-05-25 2020-07-28 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
US8987421B2 (en) * 2013-02-15 2015-03-24 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
KR102452866B1 (ko) * 2013-10-25 2022-10-07 파마싸이클릭스 엘엘씨 이식편 대 숙주 질환의 치료 및 예방 방법
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Also Published As

Publication number Publication date
US20250381188A1 (en) 2025-12-18
MX389020B (es) 2025-03-20
CA2932255C (en) 2023-10-10
US20180078558A1 (en) 2018-03-22
PH12016501051A1 (en) 2016-08-15
IL245715A0 (en) 2016-07-31
AU2020204276A1 (en) 2020-07-16
TWI743019B (zh) 2021-10-21
JP2020105181A (ja) 2020-07-09
KR20160085817A (ko) 2016-07-18
CA3210338A1 (en) 2015-06-11
AU2024278490A1 (en) 2025-01-09
US20230100137A1 (en) 2023-03-30
CN110478353A (zh) 2019-11-22
IL276683A (en) 2020-09-30
JP2024072291A (ja) 2024-05-27
US20240293409A1 (en) 2024-09-05
CN105939717B (zh) 2019-09-13
AU2022203810B2 (en) 2024-10-03
WO2015084857A1 (en) 2015-06-11
TW201605454A (zh) 2016-02-16
TW202228700A (zh) 2022-08-01
CN110478353B (zh) 2022-12-30
KR20230104754A9 (ko) 2024-11-15
CA2932255A1 (en) 2015-06-11
JP2017501140A (ja) 2017-01-12
IL292522A (en) 2022-06-01
US20150157634A1 (en) 2015-06-11
EP3076975A1 (en) 2016-10-12
JP2025118595A (ja) 2025-08-13
US20210177854A1 (en) 2021-06-17
EA201691020A1 (ru) 2017-01-30
PH12020552048A1 (en) 2022-05-11
MX2022000209A (es) 2022-02-03
AU2022203810A1 (en) 2022-06-23
AU2014360758B2 (en) 2020-03-26
BR112016012158A2 (pt) 2017-09-26
TW202402295A (zh) 2024-01-16
KR20230104754A (ko) 2023-07-10
AU2014360758A1 (en) 2016-06-16
JP2023029899A (ja) 2023-03-07
IL315228A (en) 2024-10-01
CN105939717A (zh) 2016-09-14
EP3076975A4 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
MX2016006955A (es) Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo.
ZA202208792B (en) Methods of treating and preventing graft versus host disease
EA201790398A1 (ru) Способы лечения заболевания печени
AR091700A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
HUE049442T2 (hu) Módszerek eozinofil nyelõcsõgyulladás kezelésére IL-4R inhibitor beadásával
BR112016010224A2 (pt) combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
MX374633B (es) Combinaciones terapeuticas para usarse en el tratamiento de tumores.
CL2015003731A1 (es) Inhibidores de bromodominios
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
MX2021015735A (es) Composiciones de nucleasa terapeuticas y metodos.
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
CR20160289A (es) Compuestos de inhibidor de autotaxina
MX384909B (es) Un anticuerpo anti-tau para usarse al tratar una tauopatía.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
UY33938A (es) Artículo para fumar que incluye dos o más segmentos de filtro
MX2015011386A (es) Metodo para tratar cancer pancreatico.
BR112013024363A2 (pt) método, e aparelho
BR112013029484A2 (pt) método para o tratamento de tumores sólidos avançados
MX2017010002A (es) Terapias de combinacion.
UY34341A (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EN INHIBIDOR PI3Kß Y EL INHIBIDOR DE VIA MAPK, INCLUYENDO LOS INHIBIDORES MEK Y RAF
MX2016002307A (es) Tratamiento para el cancer.
MX2016002308A (es) Tratamiento del mieloma multiple.
MX2019007354A (es) Metodos para tratar trastornos de hiperpigmentacion.